Cargando…

Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study

BACKGROUND: The measurement of CMV specific cellular immunity in organ transplant recipients could contribute additional acuity to serology based, CMV infection risk stratification, facilitating optimisation of immunosuppression and anti-viral prophylaxis. METHODS: A pilot study of renal transplant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chanouzas, Dimitrios, Small, Alexander, Borrows, Richard, Ball, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860728/ https://www.ncbi.nlm.nih.gov/pubmed/29558479 http://dx.doi.org/10.1371/journal.pone.0193968

Ejemplares similares

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients
por: Lee, Hyeyoung, et al.
Publicado: (2017)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

Impact of CMV Blips in Transplant Recipients
por: Lodding, Isabelle Paula, et al.
Publicado: (2017)

CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays
por: Amorim, Maria Luís, et al.
Publicado: (2001)

509. Role of cell-mediated immune monitoring using Interferon-γ Enzyme-linked Immunosorbent Spot Assay to predict CMV infection within six months after kidney transplantation
por: Namsiripongpan, Warunyu, et al.
Publicado: (2022)

Utility of the Enzyme-Linked Immunospot Interferon-γ–Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2016)

Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients
por: Kwon, Ji-Soo, et al.
Publicado: (2017)

Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients
por: Gliga, Smaranda, et al.
Publicado: (2021)

CS15.1 CMV in transplant recipients
por: Tan, B.-H.
Publicado: (2011)

Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
por: Kirisri, Similan, et al.
Publicado: (2021)

Combined Antigen-Specific Interferon-γ and Interleukin-2 Release Assay (FluoroSpot) for the Diagnosis of Mycobacterium tuberculosis Infection
por: Chesov, Dumitru, et al.
Publicado: (2015)

Stricturing CMV enteritis in an adult liver transplant recipient
por: Helmick, Ryan A, et al.
Publicado: (2019)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

790. The Efficacy of the Interferon-γ Releasing Assay-Based Isoniazid Treatment for Preventing Active Tuberculosis in Kidney Transplant Recipients: A Quasi-experimental Study
por: Kim, Hae-In, et al.
Publicado: (2018)

The Detection of CMV in Saliva Can Mark a Systemic Infection with CMV in Renal Transplant Recipients
por: Waters, Shelley, et al.
Publicado: (2019)

Comparing tuberculin skin test and interferon γ release assay (T-SPOT.TB) to diagnose latent tuberculosis infection in household contacts
por: Lee, Hyun Woo, et al.
Publicado: (2017)

Diagnostic Utility of Interferon-γ Release Assay in Tuberculous Lymphadenitis
por: Ye, Susu, et al.
Publicado: (2017)

1198. Measurement of Pre-transplant Anti-cytomegalovirus (CMV) Immunoglobulin G Titer to Predict Risk of CMV Infection in CMV-seropositive Kidney Transplant Recipients
por: Kirisri, Similan, et al.
Publicado: (2020)

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2021)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients
por: Sadeghi, Mahmoud, et al.
Publicado: (2016)

Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients
por: Limaye, Ajit P., et al.
Publicado: (2020)

CMV-associated adrenal insufficiency in a renal transplant recipient
por: Tejura, Nilesh, et al.
Publicado: (2017)

Thrombosis Associated With Cytomegalovirus (CMV) in a Kidney Transplant Recipient
por: Wang, Lin, et al.
Publicado: (2021)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2023)

Serial testing with an interferon-γ release assay in German healthcare workers
por: Schablon, Anja, et al.
Publicado: (2010)

Analysis of Factors Lowering Sensitivity of Interferon-γ Release Assay for Tuberculosis
por: Hang, Nguyen Thi Le, et al.
Publicado: (2011)

Serial testing with the interferon-γ release assay in Portuguese healthcare workers
por: Torres Costa, José, et al.
Publicado: (2010)

Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
por: Kay, Alexander, et al.
Publicado: (2017)

Clinical value of interferon-γ release assay in the diagnosis of active tuberculosis
por: Ai, Lu, et al.
Publicado: (2019)

Performance of Interferon-γ Release Assays in Patients with Mycobacterium kansasii Infection
por: Gao, Chun-Hai, et al.
Publicado: (2022)

Interferon-γ release assay screening in biologics: safe and reliable, but not perfect
por: Cafferkey, John, et al.
Publicado: (2022)

Tuberculin skin test and interferon‐γ release assays: Can they agree?
por: Santos, João Almeida, et al.
Publicado: (2022)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins
por: Vassallo, Francesco, et al.
Publicado: (2020)

Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update
por: Prakash, Katya, et al.
Publicado: (2021)

Long-term CMV monitoring and chronic rejection in renal transplant recipients
por: Ishikawa, Shoko, et al.
Publicado: (2023)

Prevention and management of CMV infection in pediatric solid organ transplant recipients
por: Balani, Shanthi S., et al.
Publicado: (2023)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Torque teno virus viremia and QuantiFERON(®)-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients
por: Mafi, Sarah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hqn8hnal393i17ibmg1vgulpl2